Literature DB >> 21809064

[Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis].

A Staebler1.   

Abstract

Ovarian carcinomas consist of a heterogeneous group of malignant epithelial neoplasms with specific pathogenic mechanisms. This review provides a brief introduction to the different pathways of tumor progression and the associated molecular changes. However, the main focus will be on two areas with major paradigm shifting developments in recent years. Mutational analysis of ovarian clear cell carcinomas, endometrioid carcinomas and endometriotic lesions identified mutations in the ARID1A gene as common and early genetic changes in carcinomas with associated endometriosis and in atypical endometriosis itself. Extensive pathological work-up of the fallopian tubes of BRCA1/2 mutation carriers have demonstrated the existence of serous tubal intraepithelial carcinomas (STIC). Further studies showed that this lesion can also be found in 50-60% of patients with serous ovarian carcinomas without BRCA1/2 germline mutations. Pre-precursors which share the p53 mutations with STICs but proliferate very little are called p53-signatures and provide conclusive evidence that STICs develop in the fallopian tubes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21809064     DOI: 10.1007/s00292-011-1488-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  27 in total

1.  Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.

Authors:  Jurgen M J Piek; René H M Verheijen; Paul J van Diest
Journal:  Histopathology       Date:  2009-03       Impact factor: 5.087

2.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

Review 3.  A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube.

Authors:  Mitra Mehrad; Gang Ning; Eleanor Y Chen; Karishma K Mehra; Christopher Paul Crum
Journal:  Adv Anat Pathol       Date:  2010-09       Impact factor: 3.875

4.  The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis.

Authors:  Leon Massuger; Thijs Roelofsen; Maaike van Ham; Johan Bulten
Journal:  Med Hypotheses       Date:  2009-12-21       Impact factor: 1.538

5.  Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.

Authors:  Joseph W Carlson; Elke A Jarboe; David Kindelberger; Marisa R Nucci; Michelle S Hirsch; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2010-07       Impact factor: 2.762

6.  Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.

Authors:  Annette Staebler; Bianca Karberg; Juliane Behm; Petra Kuhlmann; Ulrike Neubert; Hartmut Schmidt; Eberhard Korsching; Horst Bürger; Ralph Lelle; Ludwig Kiesel; Werner Böcker; Ie-Ming Shih; Olaf Buchweitz
Journal:  Genes Chromosomes Cancer       Date:  2006-10       Impact factor: 5.006

Review 7.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

8.  HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes.

Authors:  Jian-Jun Wei; Jingjing Wu; Chunyan Luan; Anjana Yeldandi; Peng Lee; Pacita Keh; Jinsong Liu
Journal:  Am J Surg Pathol       Date:  2010-01       Impact factor: 6.394

9.  Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.

Authors:  Emanuela Veras; Tsui-Lien Mao; Ayse Ayhan; Stefanie Ueda; Hong Lai; Mutlu Hayran; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2009-06       Impact factor: 6.394

10.  Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.

Authors:  C Blake Gilks
Journal:  J Oncol       Date:  2009-12-30       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.